Advertisement

COVID-19: Bharat Parenterals gets DCGI nod for favipiravir oral suspension

06:39 PM May 23, 2021 | PTI

Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of COVID-19 patients.

The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.

Advertisement
Advertisement

Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.

Advertisement

(To receive our E-paper on whatsapp daily, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

(To view our epaper please Read Now. For all the latest News, Mumbai, Entertainment, Cricket, Business and Featured News updates, visit Free Press Journal. Also, follow us on Twitter and Instagram and do like our Facebook page for continuous updates on the go)

Advertisement